Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (Weighted Average) (2018 - 2025)

BioNexus Gene Lab's Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $1.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $1.9 million for Q4 2025, up 4.2% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (up 4.2% YoY), and the annual figure for FY2025 was $1.9 million, up 4.2%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $1.9 million at BioNexus Gene Lab, up from $1.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $172.1 million in Q2 2022 to a low of $1.8 million in Q4 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $16.3 million (2023), against an average of $59.0 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 66.67% in 2021, then crashed 91.59% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $171.2 million in 2021, then crashed by 91.58% to $14.4 million in 2022, then rose by 10.17% to $15.9 million in 2023, then crashed by 88.78% to $1.8 million in 2024, then rose by 4.2% to $1.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $1.9 million, $1.8 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.